SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring for people with diabetes, announced today the U.S. Centers for Medicare & Medicaid Services (CMS) is ...

Approval for the technology, which integrates with a smartphone, came sooner than company officials expected. A fully mobile continuous glucose monitoring (CGM) system, which features wireless ...

Dexcom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring (CGM) for patients with diabetes, announced today that the U.S. Food and Drug Administration (FDA) has approved its G5 Mobile ...

FDA classifies this as a Class I recall, which means using the device could result in adverse health effects or death. Dexcom Inc., has recalled its G4 Platinum and G5 Mobile continuous glucose ...

San Diego, CA-based DexCom, Inc.DXCM, a renowned medical device company, announced the U.S. FDA approval for its G5 Mobile CGM (continuous glucose monitoring) system. Notably, G5 Mobile is the only ...

The FDA has approved San Diego, California-based Dexcom for a Bluetooth-enabled continuous glucose monitor (CGM), called the G5 Mobile CGM system. Correction: A previous version of this article ...

The markets seem to be happy with South San Francisco, CA-based DexCom, Inc.DXCM. The company's stock price rallied 4.8% to close at $82.62 yesterday following its announcement, that the Centers for ...

Dexcom, Inc., (NASDAQ: DXCM), a leader in continuous glucose monitoring (CGM) for patients with diabetes, announced today that the U.S. Food and Drug Administration (FDA) has approved the Dexcom G5 ® ...

Next month the FDA is hosting a public advisory committee meeting to discuss a change to the intended use of Dexcom's G5 Mobile Continuous Glucose Monitoring System (CGM) device that would allow the ...

For the first time, the US Food and Drug Administration has approved the use of a continuous glucose monitoring (CGM) system to replace finger-stick testing for determining insulin doses. The decision ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced ...

It’s a pretty good day for San Diego-based Dexcom. The company announced that it won CE Mark approval for its G5 continuous glucose monitor in the European Union. This means the device will be ...